Quick Answer
PLUS THERAPEUTICS, INC. reported Diluted EPS of $0.29 per share (loss) for fiscal year 2025.
PLUS THERAPEUTICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.29 | +87.6% |
| 2024 | -$2.34 | +44.8% |
| 2023 | -$4.24 | +63.4% |
| 2022 | -$11.58 | -943.2% |
| 2021 | -$1.11 | -82.0% |
| 2011 | -$0.61 | -1.7% |
| 2010 | -$0.60 | +7.7% |
| 2009 | -$0.65 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.04 | +89.2% | -300.0% |
| June 30, 2025 | -$0.01 | +98.6% | +99.2% |
| March 31, 2025 | -$1.19 | -58.7% | -221.6% |
| September 30, 2024 | -$0.37 | +63.0% | +47.9% |
| June 30, 2024 | -$0.71 | -20.3% | +5.3% |
| March 31, 2024 | -$0.75 | +63.8% | +25.0% |
| September 30, 2023 | -$1.00 | +64.9% | -69.5% |
| June 30, 2023 | -$0.59 | +83.4% | +71.5% |
- PLUS THERAPEUTICS, INC. showed an increase of +87.6% in Diluted EPS compared to the prior fiscal year.
- Over the 2009–2025 period, PLUS THERAPEUTICS, INC.’s diluted eps has grown by 55.4% (from $0.65 per share (loss) to $0.29 per share (loss)).
- The most recent figure is from PLUS THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: